11:07 AM EST - Medexus Pharmaceuticals Inc. : Announced that the Toronto Stock Exchange has accepted Medexus’s notice of intention to make a normal course issuer bid (NCIB). Under the NCIB, Medexus may purchase for cancellation up to $3,530,000 principal amount of its 6% unsecured convertible debentures due 2023, representing approximately 10% of the public float (defined under TSX rules) and approximately 8.5% of the $41,546,000.00 principal amount of Debentures outstanding as of January 31. Medexus Pharmaceuticals Inc.
shares T.MDP are trading down $0.02 at $3.31.
